Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corbus Pharmaceuticals ( (CRBP) ) has provided an update.
On April 7, 2026, Corbus Pharmaceuticals announced it had reached broad alignment with the U.S. Food and Drug Administration on the registration path for its Nectin-4 targeting antibody-drug conjugate CRB-701 in second-line head and neck squamous cell carcinoma and cervical cancer. The FDA feedback supported single randomized controlled registrational trials in each indication, using objective response rate as the primary endpoint for potential accelerated approval and overall survival for potential full approval, clarifying a route to late-stage development for the asset.
The company said it planned continued interactions with the FDA to finalize protocols and statistical analysis plans for these studies, as it advances CRB-701 from early proof of concept toward registrational development. Corbus also disclosed that Chief Medical Officer Dr. Dominic Smethurst had notified the company on April 1, 2026 of his resignation effective June 30, 2026, marking a leadership transition as the pipeline moves into more advanced clinical phases.
Updated monotherapy data from the ongoing Phase 1/2 study of CRB-701 in head and neck squamous cell carcinoma and cervical cancer were accepted for presentation at the American Society of Clinical Oncology 2026 Annual Meeting, including analyses of response durability and head and neck cancer subgroups. The company previously reported encouraging efficacy and safety data, and it expects to report additional results from a combination study of CRB-701 with Keytruda in first-line head and neck squamous cell carcinoma in the fourth quarter of 2026, developments that could further shape its registrational strategy.
The most recent analyst rating on (CRBP) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Corbus Pharmaceuticals stock, see the CRBP Stock Forecast page.
Spark’s Take on CRBP Stock
According to Spark, TipRanks’ AI Analyst, CRBP is a Neutral.
The score is driven by a stronger balance sheet and positive corporate updates (including extended runway into 2028), partly offset by a pre-revenue model with widening losses and increasing cash burn. Technicals add modest support due to improving near-term momentum, while negative earnings (negative P/E) weighs on valuation.
To see Spark’s full report on CRBP stock, click here.
More about Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing new therapies in oncology and obesity. Its pipeline includes CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate for Nectin-4–expressing tumors, and CRB-913, an orally delivered, peripherally restricted CB1 inverse agonist being developed for the treatment of obesity.
Headquartered in Norwood, Massachusetts, Corbus targets serious illnesses by applying innovative scientific approaches to well understood biological pathways. The company is listed on Nasdaq under the ticker CRBP and is positioning its lead oncology asset, CRB-701, for late-stage development in difficult-to-treat cancers such as head and neck squamous cell carcinoma and cervical cancer.
Average Trading Volume: 191,497
Technical Sentiment Signal: Sell
Current Market Cap: $179.8M
For a thorough assessment of CRBP stock, go to TipRanks’ Stock Analysis page.